Abstract: A novel gene (designated 101P3A11 and also referred to as PHOR-1) and its encoded protein are described. While 101P3A11 exhibits tissue specific expression in normal adult tissue, it is aberrantly expressed in prostate, colon and kidney cancers. Thus, 101P3A11 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 101P3A11 gene or fragment thereof, or its encoded protein or a fragment thereof, can be used to elicit an immune response.
Type:
Application
Filed:
October 31, 2001
Publication date:
May 15, 2003
Inventors:
Aya Jakobovits, Arthur B. Raitano, Daniel E. H. Afar, Douglas C. Saffran, Rene S. Hubert, Mary Faris, Pia M. Challita-Eid
Abstract: The invention relates to products and methods for treating cancer and for diagnosing tumorigenicity and other diseases associated with alteration in GP88 expression or action. Antagonists to an 88 KDa autocrine growth and tumorigenicity stimulator are provided which inhibit its expression or biological activity. The antagonists include antisense oligonucleotides and antibodies.
Abstract: The present invention relates to methods and compositions for the diagnosis and treatment of hematological disorders, including, but not limited to, apalstic anemia, hemophilia, sickle cell anemia, thalassisemia, blood loss and other blood disorders, e.g., blood diorders related to bone marrow irradiation or chemotherapy treatment or renal failure. The invention further provides methods for identifying a compound capable of treating a hematological disorder. The invention also provides methods for identifying a compound capable of modulating a hematopoietic cell activity. Yet further, the invention provides a method for modulating a hematopoietic cell activity. In addition, the invention provides a method for treating a subject having a hematological disorder characterized by aberrant 16319 polypeptide activity or aberrant 16319 nucleic acid expression.
Abstract: Provided are purified and isolated VEGF-C polypeptides capable of binding to at least one of KDR receptor tyrosine kinase (VEGFR-2) and Flt4 receptor tyrosine kinase (VEGFR-3); analogs of such peptides that have VEGF-C-like or VEGF-like biological activities or that are VEGF or VEGF-C inhibitors; polynucleotides encoding the polypeptides; vectors and host cells that embody the polynucleotides; pharmaceutical compositions and diagnostic reagents comprising the polypeptides; and methods of making and using the polypeptides.
Abstract: The present invention relates to sperm specific surface proteins, nucleic acid sequences encoding those proteins and antibodies raised against those proteins. Compositions comprising the sperm specific proteins or inhibitors of said proteins can be used in contraceptive applications.
Type:
Application
Filed:
July 19, 2002
Publication date:
May 8, 2003
Inventors:
Zhonglin Hao, John C. Herr, Friederike L. Jayes, Jagathpala Shetty, Michael J. Wolkowicz
Abstract: The present invention is directed to a method of treating or preventing prostate cancer in a subject in need of such a treatment by administering an inhibitor of ATP synthase activity in a pharmaceutically effective amount. The present invention also provides for a pharmaceutical composition comprising an inhibitor of ATP synthase.
Abstract: The present invention relates to a method for the prevention or treatment of a disease mediated by decreased MMP-2 function. This may result from an aberrant interaction of molecules that stimulate or inhibit MMP-2 protein synthesis, stability, or function, as well as from mutations in the coding or regulatory regions of the gene encoding MMP-2. The invention also provides a method for identifying a substance useful in this context. It further contemplates a method for diagnosing such a disease.
Abstract: Materials and methods for treating fibrosis in a mammal are disclosed. The methods comprise administering to a mammal a composition comprising a therapeutically effective amount of a zvegf3 antagonist in combination with a pharmaceutically acceptable delivery vehicle. Zvegf3 antagonists include anti-zvegf3 antibodies, mitogenically inactive receptor-binding zvegf3 variant polypeptides, and inhibitory polynucleotides. Within one embodiment of the invention the fibrosis is liver fibrosis.
Abstract: The present invention relates to targeted killing of a cell utilizing a chimeric polypeptide comprising a cell-specific targeting moiety and a signal transduction pathway factor. In a preferred embodiment, the signal transduction pathway factor is an apoptosis-inducing factor, such as granzyme B, granzyme A, or Bax.
Abstract: The present invention relates to methods and compositions for the treatment and diagnosis of pain disorders. The invention further provides methods for identifying a compound capable of treating a pain disorder. In addition, the invention provides a method for treating a subject having a pain disorder, e.g., a pain disorder characterized by aberrant 9805 polypeptide activity or aberrant 9805 nucleic acid expression.
Abstract: A method of treating a tumor (in particular osteosarcoma or Ewing's sarcoma) in a host by administering to a host or to the tumor cells an agent which inhibits cyclin G1 protein in an amount effective to inhibit cyclin G1 protein in tumor cells of the host. The agent may be an antisense polynucleotide which is complementary to at least a portion of a polynucleotide encoding cyclin G1 protein, or an antibody or fragment or derivative thereof which recognizes cyclin G1 protein. Also contemplated within the scope of the present invention are (i) the immortalization of cell lines by transducing cells with a polynucleotide encoding cyclin G1 protein; (ii) increasing the receptiveness of cells to retroviral infection by transducing cells with a polynucleotide encoding cyclin G1 protein; and (iii) the detection of cancer by detecting cyclin G1 protein or a polynucleotide encoding cyclin G1 protein in cells.
Type:
Application
Filed:
August 14, 2002
Publication date:
May 8, 2003
Applicant:
University of Southern California
Inventors:
Erlinda M. Gordon, Frederick L. Hall, W. French Anderson
Abstract: The present invention relates to methods and compositions for the treatment and diagnosis of tumorigenic and/or angiogenic disorders, including, but not limited to, lung tumors, breast tumors, ovary tumors, colon tumors, hemangioma, and metastatic and angiogenic tumors. The invention further provides methods for identifying a compound capable of treating a tumorigenic and/or angiogenic disorder or modulating tumorigenesis and/or angiogenesis. The invention also provides methods for modulating tumorigenesis and/or angiogenesis, e.g., modulating tumorigenesis and/or angiogenesis in a subject. In addition, the invention provides a method for treating a subject having a tumorigenic and/or angiogenic disorder characterized by aberrant 32616 polypeptide activity or aberrant 32616 nucleic acid expression.
Abstract: The present invention relates to compositions which specifically bind to a multimeric protein complex but not to the individual and separate components of the complex, or alternatively, compositions which specifically bind to individual and separate components but not to any complex thereof. The present invention also relates to methods of using such compositions for identifying compounds that promote multimeric complex formation and/or disruption and for treating disorders associated with aberrant complex formation by modulating the formation and/or disruption of multimeric protein complexes.
Abstract: The present invention relates to the development of insulin resistant skeletal muscle cell culture model useful for the screening of compounds that enhance insulin receptor (IR) and insulin receptor substrate-1 (IRS-1) tyrosine phosphorylation required against type II diabetes.
Abstract: Methods of treating and/or prophylaxis Alzheimer's disease by preventing the formation of cerebral amyloid due to the growth and disruption of dense microspheres (DMS) are disclosed utilizing medicaments that are effective in preventing or inhibiting the growth and disruption of DMS.
Abstract: Methods and compositions are provided for the treatment of defects and disease involving osteoporosis, or osteopenic conditions. The methods comprises applying to the site of osteoporotic or osteopenic conditions a composition comprising aBMP-3 inhibitor or antagonist. The invention further provides methods and compositions for modulating or regulating the formation of bone utilizing BMP-3 compositions.
Type:
Application
Filed:
December 3, 2001
Publication date:
May 1, 2003
Inventors:
Karen M. Lyons, Vicki Rosen, Aaron Daluiski, Thomas Engstrand, Matthew E. Bahamonde, Laura W. Gamer, Eric Agius, Karen Cox
Abstract: Methods and compositions for the treatment of ocular neovascularization and macular degeneration. The invention includes combining photodynamic therapy with administration of a neuroprotectant and a neovascularization inhibitor.
Abstract: Provided are methods of treatment for bone disorders related to bone deposition and resorption dysfunction. These bone disorders may be the result of inflammation, cancers, etc. Provided are methods of using agonists or antagonists of a cytokine molecule.
Type:
Application
Filed:
August 6, 2002
Publication date:
May 1, 2003
Inventors:
J. Fernando Bazan, Amy M. Beebe, Rene de Waal Malefyt, Daniel M. Gorman, Peter Kirk, Hirokazu Kurata, Donna Rennick
Abstract: The present invention relates to isolated and/or recombinant nucleic acids which encode primate MAdCAMs, and to proteins or polypeptides referred to herein as isolated and/or recombinant primate MAdCAMs. The invention further relates to recombinant nucleic acid constructs, comprising a nucleic acid which encodes a primate MAdCAM of the present invention, a portion thereof, or a variant; to host cells comprising such constructs, useful for the production of recombinant proteins; the use of nucleic acids and/or proteins in assays to identify inhibitors (e.g., antagonists) of primate MAdCAM function; and to antibodies reactive with primate MAdCAM, which are useful in in vitro methods, diagnostic and/or therapeutic applications.
Abstract: The present invention provides novel physiologically active protein molecules originating in mammals, which are specifically expressed in arteriosclerosis and/or coronary restenosis, and are predicted to relate closely to the onset and progress of these diseases; DNAS encoding the protein molecules; antibodies reactive with the molecules; and pharmaceutical compositions comprising the above protein molecule or the antibody. The protein molecules, DNAs, and antibodies are useful for treating and preventing arteriosclerosis.
Abstract: The role of certain cellular kinases active during Human Cytomegalovirus infection is disclosed. These cellular kinases are useful to detect HCMV infection, and can be used to screen for cellular kinase inhibitors. Cellular kinases inhibitors, which effectively downregulate these key cellular components, serve as effective therapeutics against HCMV infection.
Type:
Application
Filed:
October 16, 2001
Publication date:
May 1, 2003
Inventors:
Daniel Schubart, Peter Habenberger, Matthias Stein-Gerlach, Dorian Bevec
Abstract: The invention includes antibodies that provide superior anti-coagulant activity by binding native human TF with high affinity and specificity. Antibodies of the invention can effectively inhibit blood coagulation in vivo. Antibodies of the invention can bind native human TF, either alone or present in a TF:VIIa complex, effectively preventing factor X binding to TF or that complex, and thereby reducing blood coagulation. Preferred antibodies of the invention specifically bind a conformational epitope predominant to native human TF, which epitope provides an unexpectedly strong antibody binding site.
Type:
Application
Filed:
November 12, 2002
Publication date:
May 1, 2003
Applicant:
Sunol Molecular Corporation
Inventors:
Hing C. Wong, Jin-An Jiao, Esperanza Liliana Nieves, Lawrence Luepschen
Abstract: Conjugates are disclosed comprising a broad range helper T cell epitope portion and a B cell epitope portion from a cholesteryl ester transfer protein (CETP), which conjugates are capable of eliciting an immune response in an individual against the individual's endogenous CETP activity. The conjugates are useful in methods to inhibit CETP activity, to raise serum levels of high density lipoproteins, and to prevent or treat cardiovascular disease, such as atherosclerosis.
Type:
Grant
Filed:
October 17, 1997
Date of Patent:
April 29, 2003
Assignee:
AVANT Immunotherapeutics, Inc.
Inventors:
Charles W. Rittershaus, Lawrence J. Thomas
Abstract: A chimeric polypeptide has the formula: pTox-pTarg, wherein pTox is a viral apoptotic peptide, such as the Vpr peptide of HIV-1 or a fragment of the Vpr peptide of HIV-1 containing the amino acid motif H(F/S)RIG that interacts with mitochondrial inner membrane, adenine nucleotide translocation (ANT) protein of a cell. pTarg is an antibody or an antibody fragment that binds to the outer membrane of the cell. Binding of the chimeric polypeptide to the cell is followed by apoptosis of the cell. A vector encoding a chimeric polypeptide and a recombinant host cell comprising the vector are provided. The chimeric polypeptide is useful for targeting pTox to cells, such as cancer cells.
Type:
Application
Filed:
January 31, 2002
Publication date:
April 24, 2003
Inventors:
Lena Edelman, Etienne Daniel Francois Jacotot, Jean-Paul Briand
Abstract: The present invention relates to the prevention and treatment of injury and diseases to the liver, biliary tract, bile ducts, gall bladder and related hepatobiliary system. Specifically, the present invention relates to methods for decreasing the action of the RON receptor tyrosine kinase in liver physiology. More specifically, the present invention relates to the use of analogs and antagonists and antibodies for inhibiting the action of the RON receptor tyrosine kinase for the prevention and treatment of liver injury or damage in acute and chronic clinical conditions.
Type:
Application
Filed:
April 15, 2002
Publication date:
April 17, 2003
Applicant:
Children's Hospital Medical Center
Inventors:
Susan E. Waltz, Mike A. Leonis, Sandra J. Degen
Abstract: Problems of the present invention are to provide methods for diagnosing the morbid state based on the assay of a human airway trypsin-like protease in a biosample and to provide a therapeutic agent for diseases associated with the human airway trypsin-like protease.
Abstract: The invention relates to methods of treating a subject having Alzheimer's Disease, comprising the step of administering an antibody molecule which is targeted to &bgr; amyloid peptide or to fragment thereof. In another embodiment the invention relates to methods of treating a disease or a disorder, characterized by amyloid beta deposition. In another embodiment, the invention relates to an antibody molecule, which is free end-specific for the N-terminus or the C-terminus of an amyloid &bgr; peptide and to a pharmaceutical composition thereof. In another embodiment, the invention relates to an antibody molecule, which is targeted to the free C or N-terminus of a N-and/or C-terminus truncated amyloid &bgr; peptide fragment.
Abstract: Nucleic acid compositions encoding polypeptide products with diglyceride acyltransferase activity, as well as the polypeptide products encoded thereby and methods for producing the same, are provided. The subject polypeptide and nucleic acid compositions find use in a variety of applications, including research, diagnostic, and therapeutic agent screening applications, as well as in treatment therapies and in the production of triacylglycerols.
Type:
Application
Filed:
October 16, 2002
Publication date:
April 17, 2003
Inventors:
Robert V. Farese, Sylvaine Cases, Steven Smith, Sandra K. Erickson
Abstract: Processes for conjugating proteins with polyethylene glycol are disclosed. The disclosed processes provide modified proteins having little or no decrease in their activity and include the steps of protecting one or more sites on the protein, contacting the protected protein with polyethylene glycol under conditions suitable for conjugating the polyethylene glycol to the protein, and deprotecting the protein. This advantageous retention of a desired protein activity is attributed to the availability of one or more protein binding sites which is unaltered in the conjugation process and thus remains sterically free to interact with a binding partner ligand or cognate subsequent to the conjugation process.
Abstract: This invention is related to methods of effecting neuronal activity with non-immunosuppressive neurotrophic low molecular weight, small molecule cyclophilin inhibitor compounds having an affinity for cyclophilin-type immunophilins. The methods of this invention are useful in the stimulation of damaged neurons, promotion of neuronal regeneration, prevention of neurodegeneration, and treatment of neurological disorders.
Type:
Application
Filed:
September 7, 2001
Publication date:
April 10, 2003
Applicant:
Guilford Pharmaceuticals, Inc.
Inventors:
Gregory S. Hamilton, Ling Wei, Joseph P. Steiner
Abstract: The present invention demonstrates that a receptor, named DC-SIGN, is specifically expressed on dendritic cells, and facilitates infection of T lymphocytes with HIV. Assays for identifying compounds that modulate the interaction of DC-SIGN and HIV and/or T cells and macrophage are provided. Compounds so identified are also part of the present invention.
Type:
Application
Filed:
May 20, 2002
Publication date:
April 3, 2003
Inventors:
Dan R. Littman, Douglas Kwon, Yvette Van Kooyk, Teunis Geijtenbeek
Abstract: Compositions and methods for the therapy and diagnosis of breast, ovarian and prostate cancer are disclosed. Compositions may comprise one or more lipophilin fusion proteins, which comprise at least two different lipophilin-like polypeptides linked by a peptide bond. Such compositions may be used for the prevention and treatment of breast, ovarian and prostate cancer. Diagnostic methods based on detecting the presence of lipophilin complexes, or antibodies thereto, in a patient are also provided.
Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.
Type:
Application
Filed:
August 14, 2001
Publication date:
March 20, 2003
Applicant:
GENENTECH, INC.
Inventors:
Wei-Qiang Gao, Paul Polakis, Jianyong Shou, Victoria Smith, Robert Soriano, P. Mickey Williams, Thomas D. Wu, Zemin Zhang
Abstract: A monoclonal antibody specific for the brx gene product, Brx, implicated in the etiology of breast and ovarian cancers is disclosed. Further disclosed are methods of using this antibody to diagnose and treat proliferative disorders of reproductive and immune tissues including cancer. Methods of use of the monoclonal antibody as a molecular biological reagent for applications including but not limited to Western analysis, immunohistochemistry, immunoprecipitation, gel shift analysis, enzyme-linked immunosorption assays are also disclosed.
Abstract: The present invention describes monoclonal antibodies which are useful for the specific detection and therapy of diffuse gastric carcinoma. Further embodiments describe therapeutic and diagnostic means for the detection and for the therapy of diffuse gastric carcinomas as well as methods for the detection and therapy of diffuse gastric carcinomas.
Type:
Application
Filed:
January 14, 2002
Publication date:
March 20, 2003
Applicant:
GSF Forschungszentrum fur Umwelt und Gesundheit GmbH
Inventors:
Heinz Hofler, Karl-Friedrich Becker, Elizabeth Kremmer, Manfred Eulitz, Christoph Schuhmacher
Abstract: A novel cell surface glycoprotein, LEEP-CAM, is disclosed. This invention further provides methods for treating inflammatory disorders in mammals through the administration of compositions which are modulators of LEEP-CAM activity. Antibodies are also disclosed which prevent LEEP-CAM-mediated migration of lymphocytes into epithelial layers of cells.
Type:
Application
Filed:
January 22, 2002
Publication date:
March 13, 2003
Applicant:
The Brigham and Women's Hospital, Inc.
Inventors:
Michael B. Brenner, Christina M. Parker, Michael P. Schon
Abstract: Methods are useful for determining the effectiveness of anti-inflammatory compounds in reducing the proportion of patients exhibiting an accelerated decline in cognitive function. Reductions in decline of cognitive function in patients are provided by administering an anti-inflammatory compound.
Abstract: A method of increasing the contractility of a heart, a heart muscle or cells of a heart muscle i by administering an agent capable of binding to a phosducin binding site of G&bgr;&ggr; is provided. Said phosducin binding site is preferably a binding site of N-terminal truncated phosducin. Further, methods of identifying compounds capable of increasing the contractility of a heart muscle and methods of identifying compounds capable of inhibiting G&bgr;&ggr;-mediated processes are provided.
Type:
Application
Filed:
September 11, 2001
Publication date:
March 13, 2003
Inventors:
Martin Ungerer, Gotz Munch, Christine Baumgartner, Kai Rosport, Karl-Ludwig Laugwitz, Martin Lohse
Abstract: The present invention includes compositions and methods for the treatment of inflammatory disease (e.g., asthma, COPD, inflammatory bowel disease, atopic dermatitis, atopy, allergy, allergic rhinitis, scleroderma, and the like), relating to inhibiting a chitinase-like molecule. The invention further includes methods to identify new compounds for the treatment of inflammatory disease, including, but not limited to, asthma, COPD and the like. This is because the present invention demonstrates, for the first time, that expression of IL-13, and of a chitinase-like molecule, mediates and/or is associated with inflammatory disease and that inhibiting the chitinase-like molecule treats and even prevents, the disease. Thus, the invention relates to the novel discovery that inhibiting a chitinase-like molecule treats and prevents an inflammatory disease.
Abstract: A variety of heparanase specific molecular probes which can be used for research and medical applications including diagnosis and therapy are disclosed. Specific applications include the use of a heparanase specific molecular probe for detection of the presence, absence or level of heparanase expression; the use of a heparanase specific molecular probe for therapy of a condition associated with expression of heparanase; the use of a heparanase specific molecular probe for quantification of heparanase in a body fluid; the use of a heparanase specific molecular probe for targeted drug delivery; and, the use of a heparanase specific molecular probe as a therapeutic agent.
Type:
Grant
Filed:
June 1, 1999
Date of Patent:
March 11, 2003
Assignees:
Insight Strategy & Marketing Ltd., Hadasit Medical Research Services and Development Ltd.
Inventors:
Iris Pecker, Israel Vlodavsky, Yael Friedman, Tuvia Perets
Abstract: The present invention provides a cytokine-binding domain or portion thereof which binds to at least one cytokine and is capable of transducing a cytokine signal through a single cytokine receptor, said domain comprising a portion of the B′-C′ loop of domain 4 of a &bgr;c chain or analogous structure of a cytokine receptor. In another aspect of the invention there is provided a method of identifying a compound having cytokine agonist or antagonist activity, said method including subjecting a potential cytokine agonist and/or cytokine antagonist compound to a cytokine binding domain or portion thereof wherein said domain binds to at least one cytokine and is capable of transducing a cytokine signal through a single cytokine receptor, said domain comprising a portion of the B′-C′ loop of domain 4 of a &bgr;c chain or analogous structure of the cytokine receptor; and determining the presence of an agonist or antagonist response of the compound on the activity of a cytokine.
Type:
Application
Filed:
August 8, 2001
Publication date:
March 6, 2003
Inventors:
Jamie Rossjohn, William John McKinstry, Joanna May Woodcock, Michael William Parker, Angel Francisco Lopez, Christopher James Bagley
Abstract: The present invention provides methods for identification of cancerous cells by detection of expression levels of TTK, as well as diagnostic, prognostic and therapeutic methods that take advantage of the differential expression of these genes in mammalian cancer. Such methods can be useful in determining the ability of a subject to respond to a particular therapy, e.g., as the basis of rational therapy. In addition, the invention provides assays for identifying pharmaceuticals that modulate activity of these genes in cancers in which these genes are involved, as well as methods of inhibiting tumor growth by inhibiting activity of TTK.
Type:
Application
Filed:
February 21, 2002
Publication date:
March 6, 2003
Inventors:
Christoph Reinhard, Anne B. Jefferson, Vivien W. Chan
Abstract: A fibrin/fibrinogen binding conjugate for forming a depot for the sustained release of a pharmaceutically active substance from a fibrin clot. The conjugate comprises a fibrin/fibrinogen binding moiety bound to a pharmaceutically active substance either directly or via an intervening substance capturing moiety such as an antibody. The conjugate can also be a recombinant fusion protein comprising a fibrin/fibrinogen binding moiety such as VEGF165 C-terminal domain fused to a wound-healing substance such as leptin.
Type:
Application
Filed:
September 25, 2001
Publication date:
March 6, 2003
Inventors:
Heinz Redl, Walter Fuerst, Rudolf Kneidinger, Sam L. Helgerson, Douglas Looker, Elisabeth M. Inman, Jane P. Richards, Catalina Wong
Abstract: A method of treating pulmonary hypertension in a subject in need of such treatment comprises inhibiting EMAP II activity in the subject by an amount effective to treat the pulmonary hypertension in the subject (e.g., in the lungs and more particularly in the pulmonary vasculature). Pharmaceutical formulations useful for carrying out such methods (e.g., an antibody that specifically binds to EMAP II in a pharmaceutically acceptable carrier) and screening techniques useful for identifying additional compounds that can be used for carrying out such methods are also disclosed.
Abstract: The present invention relates to at least one novel anti-dual integrin antibodies, including isolated nucleic acids that encode at least one anti-dual integrin antibody, dual integrin, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.
Type:
Application
Filed:
August 1, 2001
Publication date:
February 27, 2003
Inventors:
George Heavner, Jill Giles-Komar, Linda Snyder, Mohit Trikha
Abstract: The invention provides methods of detection, prevention, amelioration, and treatment for angiogenesis, including angiogenesis associated with colon cancer and glioma. The methods comprise the use of an anti-A2B antibody.
Type:
Application
Filed:
August 9, 2002
Publication date:
February 20, 2003
Inventors:
Dewan Zeng, Luiz Belardinelli, Maria B. Grant
Abstract: The invention provides methods and compositions for alleviating the symptoms of neuropathic conditions with a pharmaceutical composition including an effective amount of anti-glutamic acid decarboxylase (anti-GAD) antibodies.
Abstract: The present invention is directed to monoclonal or recombinant antibodies or fragments thereof that bind to human telomerase reverse transcriptase (hTRT) protein. The present invention is also directed to methods of identifying or detecting hTRT polypeptides in biological samples. The invention is further directed to methods of generating antibodies that specifically bind to hTRT protein.
Type:
Application
Filed:
January 18, 2002
Publication date:
February 13, 2003
Inventors:
Thomas R. Cech, Joachim Lingner, Toru Nakamura, Karen B. Chapman, Gregg B. Morin, Calvin B. Harley, William H. Andrews
Abstract: Nucleic acids encoding various proteases, from a mammal, reagents related thereto, including specific antibodies, and purified proteins are described. Methods of using said reagents and related diagnostic kits are also provided.
Type:
Grant
Filed:
April 10, 2000
Date of Patent:
February 11, 2003
Assignee:
Schering Corporation
Inventors:
Lynette M. Dowling, Constance F. Huffine, Daniel M. Gorman
Abstract: The invention relates to Mycobacterium tuberculosis superoxide dismutase antibodies, methods of using them for detection of M. tuberculosis, methods of testing for an inhibitor of an M. tuberculosis superoxide dismutase, and methods of detecting tuberculosis infection.